CR20190265A - Preparación de un complejo farmacéutico que comprende amlodipina, losartán y rosuvastatina - Google Patents

Preparación de un complejo farmacéutico que comprende amlodipina, losartán y rosuvastatina

Info

Publication number: CR20190265A
Authority: CR; Costa Rica
Prior art keywords: losartan; rosuvastatin; complex preparation; active ingredients; present
Prior art date: 2016-11-15

Application number

CR20190265A

Other languages

English (en)

Spanish (es)

Inventor

Sol Ee Lim

Hyuk Jun Cho

Ho Taek Im

Yong Ll Kim

Jae Hyun Park

Jong Soo Woo

Original Assignee

Hanmi Pharm Ind Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-15

Filing date

2017-11-10

Publication date

2019-08-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190265(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-11-10 Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd

2019-08-22 Publication of CR20190265A publication Critical patent/CR20190265A/es

Links

238000002360 preparation method Methods 0.000 title abstract 9
239000002083 C09CA01 - Losartan Substances 0.000 title abstract 5
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 5
229960000528 amlodipine Drugs 0.000 title abstract 5
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 title abstract 5
229960004773 losartan Drugs 0.000 title abstract 5
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 5
229960000672 rosuvastatin Drugs 0.000 title abstract 5
239000004480 active ingredient Substances 0.000 abstract 6
208000024172 Cardiovascular disease Diseases 0.000 abstract 2
238000004090 dissolution Methods 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
230000000069 prophylactic effect Effects 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CR20190265A 2016-11-15 2017-11-10 Preparación de un complejo farmacéutico que comprende amlodipina, losartán y rosuvastatina CR20190265A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR1020160152077		2016-11-15
PCT/KR2017/012703 WO2018093096A2 (fr)	2016-11-15	2017-11-10	Préparation de complexe pharmaceutique comprenant de l'amlodipine, du losartan et de la rosuvastatine

Publications (1)

Publication Number	Publication Date
CR20190265A true CR20190265A (es)	2019-08-22

Family

ID=62146632

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20190265A CR20190265A (es)	2016-11-15	2017-11-10	Preparación de un complejo farmacéutico que comprende amlodipina, losartán y rosuvastatina

Country Status (11)

Country	Link
CO (1)	CO2019004796A2 (fr)
CR (1)	CR20190265A (fr)
DO (1)	DOP2019000092A (fr)
EA (1)	EA201991190A1 (fr)
EC (1)	ECSP19040732A (fr)
MX (1)	MX2019005230A (fr)
NI (1)	NI201900048A (fr)
PH (1)	PH12019500779A1 (fr)
SG (1)	SG11201903132YA (fr)
WO (1)	WO2018093096A2 (fr)
ZA (1)	ZA201902720B (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007112288A2 (fr) *	2006-03-23	2007-10-04	Mount Sinai School Of Medicine	Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer
KR101298788B1 (ko) *	2011-03-15	2013-08-22	보령제약 주식회사	안정성이 개선된 복합제제
MX358211B (es) *	2012-07-23	2018-08-10	Landsteiner Scient S A De C V	Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
KR101910901B1 (ko) *	2013-11-29	2018-10-24	한미약품 주식회사	암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) *	2014-09-30	2022-03-03	한미약품 주식회사	암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물

2017
- 2017-11-10 WO PCT/KR2017/012703 patent/WO2018093096A2/fr not_active Ceased
- 2017-11-10 EA EA201991190A patent/EA201991190A1/ru unknown
- 2017-11-10 CR CR20190265A patent/CR20190265A/es unknown
- 2017-11-10 SG SG11201903132YA patent/SG11201903132YA/en unknown
- 2017-11-10 MX MX2019005230A patent/MX2019005230A/es unknown
2019
- 2019-04-11 PH PH12019500779A patent/PH12019500779A1/en unknown
- 2019-04-11 DO DO2019000092A patent/DOP2019000092A/es unknown
- 2019-04-30 ZA ZA2019/02720A patent/ZA201902720B/en unknown
- 2019-05-10 CO CONC2019/0004796A patent/CO2019004796A2/es unknown
- 2019-05-14 NI NI201900048A patent/NI201900048A/es unknown
- 2019-06-11 EC ECSENADI201940732A patent/ECSP19040732A/es unknown

Also Published As

Publication number	Publication date
CO2019004796A2 (es)	2019-05-21
ZA201902720B (en)	2020-08-26
PH12019500779A1 (en)	2019-07-29
MX2019005230A (es)	2019-08-14
EA201991190A1 (ru)	2019-10-31
DOP2019000092A (es)	2019-09-30
WO2018093096A3 (fr)	2018-07-26
NI201900048A (es)	2019-10-11
WO2018093096A2 (fr)	2018-05-24
SG11201903132YA (en)	2019-05-30
ECSP19040732A (es)	2019-07-31

Similar Documents

Publication	Publication Date	Title
MX2020010737A (es)	2020-11-09	Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2016002269A1 (es)	2017-08-18	Moduladores alostéricos del núcleo proteico de la hepatitis b.
MX383227B (es)	2025-03-13	Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
MX386615B (es)	2025-03-19	Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis.
MX390001B (es)	2025-03-19	Composiciones de bebida lista para beber estables que comprende agentes activos lipofilos.
CL2016001918A1 (es)	2017-01-13	Heteroaril amidas como inhibidores de agregación de proteína
ECSP19038749A (es)	2019-06-30	Formulación de complejo farmacéutica que comprende amlodipina, losartán y clortalidona
UY37342A (es)	2018-01-31	Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CL2017003437A1 (es)	2018-06-22	Formulación solida oral que contiene irinotecán y método de preparación de la misma
CL2017001964A1 (es)	2018-02-16	Encapsulado de agentes activos de alta potencia.
CO2017012645A2 (es)	2018-04-10	Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
IL266279B1 (en)	2023-03-01	Stable aqueous capsaicin injectable formuatlions and medical uses thereof
DOP2019000257A (es)	2020-09-15	Combinación farmacéutica que comprende ponesimod
MX376118B (es)	2025-03-07	Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
HUE057871T2 (hu)	2022-06-28	Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
CO2018002428A2 (es)	2018-07-10	Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
MX388400B (es)	2025-03-20	Una composición de dos componentes, que comprende ácido acetilsalicílico.
DOP2019000015A (es)	2019-05-15	Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
ECSP19040732A (es)	2019-07-31	Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina
EA201891848A1 (ru)	2019-02-28	Фармацевтическая композиция для применения в лечении фиброза
MX374540B (es)	2025-03-06	Desmopresina estabilizada.
PY1749400A (es)	2019-01-01	Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
UA98822U (en)	2015-05-12	APPLICATION OF KAPIKOR (MELDONIUM DIHYDRATE AND γ-BUTYROBETAINE DIHYDRATE) MEDICINE AS THE ENDOTHELIUM PROTECTOR WITH ANTI-ISCHEMIC EFFECT
UA100710U (xx)	2015-08-10	Застосування капсул "фітовенол" як гепатопротекторного засобу